Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

COYA

Coya Therapeutics (COYA)

Coya Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:COYA
DateTimeSourceHeadlineSymbolCompany
28/05/202422:15Business WireCoya Therapeutics Announces Inclusion in the MSCI USA Micro Cap IndexNASDAQ:COYACoya Therapeutics Inc
22/05/202422:15Business WireCoya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s DiseaseNASDAQ:COYACoya Therapeutics Inc
21/05/202407:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
20/05/202422:15Business WireCoya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)NASDAQ:COYACoya Therapeutics Inc
10/05/202406:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COYACoya Therapeutics Inc
10/05/202406:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
10/05/202406:10Business WireCoya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial ResultsNASDAQ:COYACoya Therapeutics Inc
09/05/202407:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
26/04/202422:15Business WireCoya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumNASDAQ:COYACoya Therapeutics Inc
22/04/202422:15Business WireCoya Therapeutics to Participate in the Mizuho Neuroscience SummitNASDAQ:COYACoya Therapeutics Inc
18/04/202422:15Business WireCoya Therapeutics to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:COYACoya Therapeutics Inc
08/04/202422:15Business WireCoya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumNASDAQ:COYACoya Therapeutics Inc
19/03/202423:15Business WireCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial ResultsNASDAQ:COYACoya Therapeutics Inc
13/03/202400:00Business WireCoya Therapeutics to Participate in BTIG Fireside DiscussionNASDAQ:COYACoya Therapeutics Inc
12/03/202423:00Business WireCoya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
07/03/202400:15Business WireCoya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 ConferenceNASDAQ:COYACoya Therapeutics Inc
06/03/202412:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
01/03/202400:15Business WireCoya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceNASDAQ:COYACoya Therapeutics Inc
23/02/202400:15Business WireCoya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
22/02/202400:15Business WireCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”NASDAQ:COYACoya Therapeutics Inc
14/02/202400:15Business WireCoya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory DiseasesNASDAQ:COYACoya Therapeutics Inc
03/02/202412:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
03/02/202412:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
30/01/202400:15Business WireCoya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology ConferenceNASDAQ:COYACoya Therapeutics Inc
20/01/202410:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
20/01/202410:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
20/01/202410:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COYACoya Therapeutics Inc
20/01/202400:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COYACoya Therapeutics Inc
19/01/202400:15Business WireCoya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call SeriesNASDAQ:COYACoya Therapeutics Inc
17/01/202408:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COYACoya Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:COYA